Christmas Breakfast – What’s Happening in Flemingsberg?

Earlier this week, the Flemingsberg Science Foundation hosted its annual Christmas breakfast with the theme “What’s Happening in Flemingsberg,” aimed at informing, inspiring, and networking. The breakfast is organized within the framework of the foundation’s Business Community, which aims to create meeting places for companies and organizations in the area.

Participants had the opportunity to start the day with a Christmas-inspired breakfast while receiving the latest news about what is happening in Flemingsberg.

For those already active in the area, this is a chance to network and get to know their neighbors better. For others, the breakfast is an opportunity to discover Flemingsberg and gain insight into all the exciting developments, from new establishments to innovative initiatives.

Kalle Ottosson from the Royal Opera shared news about the Opera and Dramaten’s new establishment in Flemingsberg, and Lindsay Davies talked about the newly started company QVance in Flemingsberg.

The Flemingsberg Science Foundation would like to extend a big thank you to everyone who participated and contributed to inspiring conversations and valuable networking.

Portabel Health: Crowned Winner of Flemingsberg Science STARTUP Award 2025

Quickly finding the right personnel is one of the healthcare sector’s major challenges, especially in times of staff shortages and increasing demands for efficiency. Portabel Health offers a modern solution to these problems through a digital platform that makes it easy for care providers to access qualified nurses and healthcare professionals.

Press Start: The Game Hub in Flemingsberg – Finally!

On April 24th, after just two months of hard work, it was finally time for the kick-off for the game cluster Press Start. The initiative is led by Drivhuset, in close collaboration with Flemingsberg Science Foundation and Södertörn University's Innovation Station.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Previous 456 Next